Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Vivek Subbiah
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Vivek Subbiah
Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘
read more ↘
Login to view comments.
Click here to Login